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Abstract—The reaction of cyanothioacetamide with aromatic aldehydes and 1,3-dicarbonyl compounds followed 
by aminomethylation or S-alkylation gave a series of heterocyclic derivatives with a 1,2,3,4-tetrahydropyridine 
or 1,4,5,6,7,8-hexahydroquinoline fragment. The resulting compounds were tested for analgesic activity in vivo. 
Some of the prepared compounds showed an antinociceptive effect superior to that of ketorolac in dynamics.
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Cyanothioacetamide 1 is a readily available and 
multifunctional reagent widely used in synthetic organic 
chemistry [1–4]. One of the main directions of the use 
of thioamide 1 is the preparation of a wide range of S,N-
heterocyclic compounds, the most important of which 
are 3-cyanopyridine-2(1H)-thiones 2 [5–11] (Scheme 1). 
Compounds 2 are a convenient scaffolds for the synthesis 
of a wide range of thieno[2,3-b]pyridines [12–20], 
thiazolo[3,2-a]pyridines [21–29], pyrido[2,1-b][1,3,5]-
thiadiazines [30 –34], dipyrido[1,2-a:1'2'-e][1,3,5,7]-
tetrazocines [35], pyrido[1,2-a][1,3,5] triazines [36], 
isothiazolo[5,4-b]pyridines [37–40], and other bi- and 
polycyclic structures.
Many of the compounds obtained in this way exhibit 
valuable practical properties. In particular, pyrido[2,1-b]-
[1,3,5]thiadiazine derivatives 3 (Scheme 2) show 
high activity against tick-borne encephalitis virus 
and Powassan virus [41], exhibit a pronounced anti-
infl ammatory effect [42], analeptic [43] and adaptogenic 
effect [44]. Disulfi des 4 (Hlg = F, Br) have moderate anti-
HIV activity [45], compounds 5 and 6 are inhibitors of 
autotaxin [46], while hexahydroquinoline 7 inhibits beta-
amyloid peptide formation [47], which is considered one 
of the main factors in the development of the Alzheimer’s 
disease.
The broad spectrum of biological activity found in 
partially saturated nicotinonitrile derivatives readily 
available from α-cyanothioacetamide stimulates further 
research in the search for new biologically active 
substances in this series.
The aim of this work was to synthesize new structural 
analogs of compounds 3–7 and study their analgesic 
activity in vivo (rats). Cyanothioacetamide derivatives 
were selected for our research based on in silico 
assessment of bioavailability parameters and potential 
targets using open software packages OSIRIS Property 
Explorer [48], SwissADME [49], SwissTargetPrediction 
[50], Molinspiration Property Calculation Service 
[51], and admetSAR [52]. Thus, we selected 6 new 
compounds from a small (250+ compounds) library of 
structural analogs of 3–7, namely pyrido[2,1-b][1,3,5]-
thiadiazines 8а–8c, α-(hetarylthio)acetanilides 9, 10, and 
hexahydroquinoline 11 (Scheme 3).
The syntheses of compounds 8–11 are depicted in 
Schemes 4–6. Thus, pyrido[2,1-b][1,3,5]thiadiazines 
8а–8c (Scheme 4) were prepared in 4 steps, starting 
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from cyanothioacetamide 1. The reaction of thioamide 
1 with 3-methoxy-4-ethoxybenzaldehyde afforded 
thioacrylamide 12, which reacted without isolation with 
Meldrum acid 13 to form the corresponding Michael 
adduct 14. The latter underwent cyclization upon 
refl uxing in ethanol with the elimination of acetone 
and CO2 and the formation of tetrahydropyridine-2-
thiolate 15. Treatment of the latter with primary amines 
Scheme 1.
Scheme 2.
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in the presence of an excess of formaldehyde under 
mild conditions resulted in the formation of the target 
pyrido[2,1-b][1,3,5]thiadiazines 8а–8c in high yields.
Compound 9 was synthesized by reacting cyanothio-
acetamide 1 with cyclohexane-1,3-dione and vanillin 
in three steps similar to the known procedure with 
intermediate isolation of mercaptoquinoline 16 [53] 
(Scheme 5). Hexahydroquinoline 11 was obtained 
by a modified method described in [54]. Finally, 
tetrahydropyridine 10 was prepared similar to procedure 
reported in [55, 56] (Scheme 6).
Compounds 8а–8c, 9–11 are fi ne crystalline substances 
of white or beige color, poorly soluble in ethanol and 
diethyl ether, soluble in acetone and DMSO. Their 
structure was confi rmed by a complex of 1H, 13C DEPTQ 
NMR and IR spectral data, as well as high-resolution mass 
spectrometry method. In addition, structure of compounds 
8c and 9 was proved using two-dimensional NMR 
spectroscopy methods (1H–13C HSQC, 1H–13C HMBC) 
(Tables 1, 2). The complete set of observed correlations 
and signal assignments are presented in Supplementary 
Information.
Analgesic activity of compounds 8–11 was studied 
in vivo using the well-known thermal tail immersion test 
[57–60], as well as classical formalin-induced orofacial 
trigeminal pain test [61–65]. The average time of the 
tail withdrawal from a vessel with hot water in rats 
without pharmacological correction is 3.57 s (Table 3). 
Preliminary administration of ketorolac to rats of the 
reference group signifi cantly increased this value to 
10.92 s.
In was found that hexahydroquinolines 9 (10.15 s) 
and 11 (10.90 s) show the most pronounced analgesic 
activity. Pyrido[2,1-b][1,3,5]thiadiazines 8a–8c have 
moderate analgesic activity and increase more than two 
times the tail fl ick time in the heat immersion test. In 
contrast, pyridine derivative 10 does not exhibit analgesic 
properties.
Data on analgesic activity in the orofacial trigeminal 
pain test are presented in Table 4. Thus, in 10 min we 
Scheme 3.
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recorded an average of 173 scratching movements of 
the orofacial area in rats of the control group. In 15 min 
this value was 250, and in 20 min—294 movements. 
Preliminary administration of ketorolac to rats of the 
reference group decreased the frequency of scratching 
movements by 41.04% in 10 min in comparison with 
the control (Table 4). A 15-min time interval after the 
introduction of algogen into the vibrissa region in rats 
of this group showed a decrease in this value by 46.6%. 
Within 20 min, the frequency of scratching movements 
decreased by 43.23% compared with the control.
Compounds 9 and 11 showed the highest analgesic 
activity in the orofacial trigeminal pain test already in the 
fi rst 10 min, while compounds 8a and b showed effect 
comparable to the reference drug (ketorolac). Within a 
15-min interval after the administration of algogen, the 
leader in analgesic activity was compound 11, which was 
19.3% more effective than ketorolac. Hexahydroquinoline 
derivative 9 showed an activity exceeding that of 
ketorolac by 14.66%. Compound 8b exhibited activity 
comparable to ketorolac. Finally, within a 20-min interval 
after the injection of formalin solution into the vibrissa 
area, the maximum analgesic activity was revealed for 
hexahydroquinolines 9 and 11. They exceed the reference 
drug in analgesic activity by 24.4 and 16.5%, respectively. 
The analgesic activity of compound 8b also slightly 
exceeds that of ketorolac.
In the orofacial trigeminal pain test, pyridothiadiazine 
derivative 8c showed low analgesic activity; we did 
not fi nd signifi cant differences in comparison with the 
control group of animals. Compound 10 at a similar dose 
did not show any analgesic effect, since at none of the 
Scheme 4.
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indicated time intervals this compound did not reduce 
the number of scratching movements. Full data on the 
biological activity of compounds 8–11 are presented in 
Supplementary Materials.
In summary, the reaction of α-cyanothioacetamide 
with aldehydes and 1,3-dicarbonyl compounds followed 
by functionalization (aminomethylation or S-alkylation 
of intermediates) provided new heterocyclic compounds 
Scheme 5.
Scheme 6.
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containing tetrahydropyridine or hexahydroquinoline 
fragments. The biological screening showed the presence 
of the most pronounced analgesic activity at a dose of 5 





hexahydroquinoline-3-carbonitrile. In addition, pyrido-
[2,1-b][1,3,5]thiadiazine derivatives showed analgesic 
activity comparable to that of ketorolac.
EXPERIMENTAL
IR spectra were registered on a Bruker Vertex 70 
spectrometer equipped with an ATR sample accessory. 
NMR spectra were recorded on a Bruker Avance III HD 
400 MHz instrument [400.17 (1H), 100.63 MHz (13C)] 
using DMSO-d6 as a solvent; residual solvent signals were 
used as a standard. High-resolution mass spectra (HRMS) 
were recorded on a Bruker maXis Impact quadrupole 
TOF mass spectrometer using a MeCN–water system, 
HCO2Na–HCO2H calibration, and ESI-TOF ionization. 
Individuality of the obtained compounds was monitored 
by TLC on Silufol UV-254 plates, eluting with acetone–
hexane mixture (1 : 1) and developing with iodine vapor 
or UV light.
Cyanothioacetamide 1 [66] and Meldrum’s   acid 13 
[67] were prepared according to the known methods.
General procedure for the synthesis of 3-aryl-
8-(3-methoxy4-ethoxyphenyl)-6-oxo-2,3,4,6,7,8-
hexahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbo-
nitriles 8а–8c. N-Methylmorpholine (2 drops) was 
added with stirring to a mixture of 3-methoxy-4-ethoxy-
benzaldehyde (1.8 g, 10 mmol) and cyanothioacetamide 
1 (1.0, 10 mmol) in 15 mL of ethanol. The resulting 
mixture was stirred until complete conversion, while 
the formation of a yellow-orange precipitate of the 
Table 1. Correlations in the 1H–13C HSQC and 1H–13C HMBC NMR spectra of compound 8c
δН, ppm
δС, ppm
1H–13C HSQC 1H–13C HMBC 
1.30 t (3Н, OCH2CH3) 14.8* (CH3CH2O) 63.6 (CH3CH2O)
2.69 d. d (1H, cis-С7H) 38.2 (C7H2) 37.3* (C8H), 88.7 (C9), 132.1 (C1 C-Ar), 167.3 (C=O)
3.02 d. d (1H, trans-С7H) 38.2 (C7H2) 37.3* (C8H), 88.7 (C9), 132.1 (C1 C-Ar), 167.3 (C=O)
3.71 s (3H, MeO) 55.3* (CH3O C-Ar) 149.0 (C3–OMe C-Ar)
3.74 s (3H, MeO) 55.4* (4-CH3O N-Ar) 157.1 (C4–OMe N-Ar)
3.79 s (3H, MeO) 55.7* (2-CH3O N-Ar) 152.8 (C2–OMe N-Ar)
3.83–3.85 m (1H, С8H) 37.3* (C8H) 38.2 (C7H2), 88.7 (C9), 111.0* (C2H C-Ar), 117.9 (C≡N), 
132.1 (C1 C-Ar), 149.3 (C9a), 167.3 (C=O).
3.96 q (OCH2CH3) 63.6 (CH3CH2O) 14.8* (CH3CH2O), 147.3 (C4-OEt C-Ar)
5.10–5.28 m (4Н, NСН2NCH2S) 54.7 (C2H2), 60.4 (C4H2) 54.7 (C2H2), 60.4 (C4H2), 127.3 (C1 N-Ar), 149.3 (C9a), 
167.3 (C=O)
6.42–6.48 m (2H, H5 N-Ar, H6 
C-Ar)
104.2* (C5H N-Ar, 118.2* 
(C6H C-Ar)
37.3* (C8H), 100.0* (C3H N-Ar), 111.0* (C2H C-Ar), 127.3 
(C1 N-Ar), 147.3 (C4-OEt C-Ar), 157.1 (C4–OMe N-Ar)
6.60 d (1H, H3 N-Ar) 100.0* (C3H N-Ar) 104.2* (C5H N-Ar), 127.3 (C1 N-Ar), 152.8 (C2–OMe 
N-Ar), 157.1 (C4–OMe N-Ar)
6.75 d (1H, H5 C-Ar) 112.6* (C5H C-Ar) 132.1 (C1 C-Ar), 149.0 (C3–OMe C-Ar)
6.79 d (1H, H2 C-Ar) 111.0* (C2H C-Ar) 37.3* (C8H), 118.2* (C6H C-Ar), 147.3 (C4-OEt C-Ar), 
149.0 (C3–OMe C-Ar)
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Knoevenagel condensation product, 3-(3-methoxy-4-
ethoxyphenyl)-2-cyanothioacrylamide 12, was observed. 
To a suspension of thioacrylamide 12 were added 1.50 g 
(10.4 mmol) of Meldrum acid 13, 10 mL of ethanol 
and 1.65 mL (15 mmol) of N-methylmorpholine. The 
suspension was stirred until the reaction completed 
(control by TLC, color change from orange to white). 
A suspension of Michael adduct 14 was boiled with 
vigorous stirring until a clear yellow-orange solution was 
formed and then for another 30 min until the reaction was 
Table 2. Correlations in the 1H–13C HSQC and 1H–13C HMBC NMR spectra of compound 9
δН, ppm
δС, ppm
1H–13C HSQC 1H–13C HMBC 
1.75–1.93 m (2Н, C7H2) 20.7 (C7H2) 151.3 (C8a), 194.9 (C=O)
2.21–2.25 m (2Н, C6H2) 36.7 (C6H2) 20.7 (C7H2), 26.3 (C8H2), 194.9 (C=O)
2.49–2.59 m (2Н, C8H2) 26.3 (C8H2) 20.7 (C7H2), 109.2 (C4a), 151.3 (C8a)
3.70 s (3H, MeO) 55.5* (OMe) 147.4 (C5–OMe Ar)
3.90 q (2H, SCH2) 36.8 (SCH2) 142.1 (C2), 166.6 (C(O)NH)
4.40 s (1H, H4) 38.6* (C4H) 92.0 (C3), 109.2 (C4a), 111.5* (C2H Ar), 119.4* (C6H Ar), 
136.1 (C1 Ar), 142.1 (C2), 151.3 (C8a), 194.9 (C=O)
6.53 d. d (1H, H6 Ar) 119.4* (C6H Ar) 38.6* (C4H), 111.5* (C2H Ar), 145.5 (C4–OH Ar)
6.64 d (1H, H5 Ar) 115.4* (C5H Ar) 136.1 (C1 Ar), 145.5 (C4–OH Ar), 147.4 (C5–OMe Ar)
6.70 d (1H, H2 Ar) 111.5* (C2H Ar) 38.6* (C4H), 119.4* (C6H Ar), 136.1 (C1 Ar), 145.5 (C4–OH 
Ar), 147.4 (C5–OMe Ar)
7.14–7.18 m (2H, H3, H5 
4-FC6H4)
115.5* d (С3H, C5H 4-FC6H4) 115.5* d (С3H, C5H 4-FC6H4), 134.8 d (С1 4-FC6H4), 158.3 d 
(С4 4-FC6H4)
7.52–7.56 m (2H, H2, H6 
4-FC6H4)
121.4* d (С2H, C6H 4-FC6H4) 121.4* d (С2H, C6H 4-FC6H4), 134.8 d (С1 4-FC6H4), 158.3 d 
(С4 4-FC6H4)
8.86 s (1H, OH) – 115.4* (C5H Ar), 145.5 (C4–OH Ar), 147.4 (C5–OMe Ar)
9.99 s (1H, N1H) – 26.3 (C8H2), 92.0 (C3), 109.2 (C4a), 151.3 (C8a)
10.39 s [1H, C(O)NH] – 121.4* d (С2H, C6H 4-FC6H4), 134.8 d (С1 4-FC6H4), 166.6 
[C(O)NH]
Table 3. Analgesic activity of compounds 8–11 in the test of thermal immersion of the tail in rats
Compound Tail withdrawal time measurement results, saverage value standard deviation median value ра
Control 3.57 1.16 3.85 –
Ketorolac 10.92 2.36 10.10 0.03
8а 8.68 2.79 8.45 0.03
8b 9.20 4.74 10.00 0.03
8c 7.60 2.65 7.50 0.03
9 10.15 2.67 10.75 0.03
10 3.52 1.61 3.40 0.92
11 10.90 3.96 8.95 0.03
a р—reliability of the results in comparison with the control group of animals.
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complete. The hot reaction mixture was evaporated to 1/3 
of the volume in vacuum, while N-methylmorpholinium 
4-(3-methoxy-4-ethoxyphenyl)-6-oxo-3-cyano1,4,5,6-
tetrahydropyridine-2-thiolate 15 crystallized. Yield 2.8 g 
(69%), pale yellow crystals. Thiolate 15 was used without 
further purifi cation. 1Н NMR spectrum, δ, ppm: 1.29 t 
(3Н, OCH2CH3, 3J = 7.0 Hz), 2.35 d. d (1H, cis-С5H, 
2J = 16.1, 3J = 4.4 Hz), 2.66 d. d (1H, trans-С5H, 2J = 
16.1, 3J = 6.9 Hz), 2.78 s (3H, NCH3), 3.13–3.22 m (4H, 
CH2NCH2), 3.56 d. d (1H, С4H, 3J = 6.9, 3J = 4.4 Hz), 
3.71 s (3H, MeO), 3.71–3.80 m (4H, CH2OCH2), 3.95 q 
(OCH2CH3, 3J = 7.0 Hz), 6.64 d. d (1H, H-Ar, 3J = 8.1, 
4J = 1.6 Hz), 6.78 d (1H, H-Ar, 4J = 1.6 Hz), 6.83 d (1H, 
H-Ar, 3J = 8.1 Hz), 8.55 br. s (1H, NH), 9.61 v. br. s 
(1Н, NH+).
Thiolate 15 (0.5 g, 1.2 mmol) was dissolved by 
heating in 10 mL of 70% ethanol and fi ltered through 
a paper fi lter to obtain a clear solution. To the resulting 
solution was added the corresponding substituted aniline 
(1.2 mmol) and an excess of 37% aqueous HCHO (1 mL, 
13.3 mmol). The mixture was refl uxed with vigorous 
stirring for 2–3 min until crystallization of the reaction 
product, then cooled to room temperature and kept for 
6 h. The precipitate was fi ltered off, washed with water, 
cooled ethanol, and diethyl ether. If necessary, it was 
purifi ed by recrystallization from acetone.
8-(3-Methoxy-4-ethoxyphenyl)-3-(4-ethylphenyl)-
6-oxo-2,3,4,6,7,8-hexahydropyrido[2,1-b][1,3,5]-
thiadiazine-9-carbonitrile (8a). Yield 87%, colorless 
crystals. IR spectrum, ν, cm–1: 2193 s (С≡N), 1691 s 
(С=О). 1Н NMR spectrum, δ, ppm: 1.16 t (3Н, 
ArCH2CH3, 3J = 7.6 Hz), 1.30 t (3Н, OCH2CH3, 3J = 
7.0 Hz), 2.55 q (ArCH2CH3, 3J = 7.6 Hz), 2.70 d. d (1H, 
cis-С7H, 2J = 16.0, 3J = 5.1 Hz), 3.00 d. d (1H, trans-С7H, 
2J = 16.0, 3J = 7.1 Hz), 3.69 s (3H, MeO), 3.80 d. d (1H, 
С8H, 3J = 7.1, 3J = 5.1 Hz), 3.96 q (2H, OCH2CH3, 3J = 
7.0 Hz), 5.33 d (1Н, СН2S, 2J = 12.5 Hz), 5.39–5.42 m 
(3Н, СН2NCH2S), 6.45 d. d (1H, H-Ar, 3J = 8.3, 4J = 2.0 
Hz), 6.73 d (1H, H-Ar, 3J = 8.3 Hz), 6.78 d (1H, H-Ar, 
4J = 2.0 Hz), 7.00 d (2H, H-Ar, 3J = 8.6 Hz), 7.16 d 
(2H, H-Ar, 3J = 8.6 Hz). 13С DEPTQ NMR spectrum, 
δC, ppm: 14.8* (CH3CH2O), 15.6* (CH3CH2Ar), 27.2 
(CH3CH2Ar), 37.4* (C8H), 38.1 (C7H2), 52.6 (C2H2), 
55.4* (CH3O), 57.8 (C4H2), 63.6 (CH3CH2O), 89.3 (C9), 
111.1* (CH Ar), 112.7* (CH Ar), 116.5* (2C, C2, C6 
4-EtC6H4), 117.6 (C≡N), 128.8* (2C, C3, C5 4-EtC6H4), 
131.9 (C Ar), 136.8 (C Ar), 141.5 (C Ar), 147.3 (C4-OEt 
C-Ar), 148.8 (C3–OMe C-Ar), 149.1 (C9a), 167.3 (C=O). 
Hereinafter, an asterisk denotes signals in antiphase. 
Mass spectrum (HRMS ESI-TOF), m/z: 472.1663 [M + 
Na]+ (calcd. for C25H27N3NaO3S: 472.1665), 540.1553 




[1,3,5]thiadiazine-9-carbonitrile (8b). Yield 87%, 
colorless crystals. IR spectrum, ν, cm–1: 2191 s (С≡N), 
1689 s (С=О). 1Н NMR spectrum, δ, ppm: 1.30 t (3Н, 
OCH2CH3, 3J = 7.0 Hz), 2.16 s (3H, Me-Ar), 2.17 s 
(3H, Me-Ar), 2.70 d. d (1H, cis-С7H, 2J = 16.1, 3J = 
5.0 Hz), 2.99 d. d (1H, trans-С7H, 2J = 16.1, 3J = 7.1 
Hz), 3.68 s (3H, MeO), 3.79 d. d (1H, С8H, 3J = 7.1, 3J = 
5.0 Hz), 3.96 q (2H, OCH2CH3, 3J = 7.0 Hz), 5.29–5.44 m 
(4Н, NСН2NCH2S), 6.43 d. d (1H, H-Ar, 3J = 8.1, 4J = 
2.0 Hz), 6.76–6.79 m (2H, H-Ar), 6.91 d (1H, H-Ar, 4J = 
2.5 Hz), 7.06 d (1H, H-Ar, 3J = 8.3 Hz). 13С DEPTQ NMR 
spectrum, δC, ppm: 14.8* (CH3CH2O), 18.4* (CH3Ar), 
Table 4. Analgesic activity of compounds 8–11 in the test of orofacial trigeminal pain in rats
Compound 




















Control 173.50 35.77 183.00 – 250.83 40.89 243.50 – 294.33 61.78 296.50 –
Ketorolac 102.33 20.78 98.50 0.03 133.50 34.05 124.50 0.03 166.33 45.31 167.00 0.03
8а 121.00 40.77 102.00 0.17 156.00 55.43 131.50 0.04 199.50 59.78 184.00 0.03
8b 103.17 24.60 99.50 0.03 133.83 26.92 135.00 0.03 161.67 30.50 161.00 0.03
8c 152.67 33.24 151.50 0.46 219.67 84.08 196.00 0.46 276.33 106.59 262.00 0.60
9 84.00 24.71 87.00 0.03 113.50 30.68 120.50 0.03 138.67 23.69 144.50 0.03
10 173.67 26.25 172.00 0.75 240.67 32.57 239.50 0.69 287.50 31.69 290.00 0.83
11 87.50 27.04 89.00 0.03 107.33 23.63 104.50 0.03 125.50 28.59 116.50 0.03
a р—reliability of the results in comparison with the control group of animals.
RUSSIAN  JOURNAL  OF  GENERAL  CHEMISTRY  Vol.  91  No.  2  2021
162 BIBIK et al.
19.9* (CH3Ar), 37.4* (C8H), 38.1 (C7H2), 52.6 (C2H2), 
55.4* (CH3O), 57.9 (C4H2), 63.6 (CH3CH2O), 89.1 (C9), 
111.1* (CH Ar), 112.7* (CH Ar), 113.9* (CH Ar), 117.6 
(C≡N), 117.8* (CH Ar), 118.3* (CH Ar), 129.2 (C Ar), 
130.4* (CH Ar), 132.0 (C Ar), 137.2 (C Ar), 141.6 (C 
Ar), 147.3 (C4-OEt C-Ar), 148.9 (C3–OMe C-Ar), 149.1 
(C9a), 167.3 (C=O). Mass spectrum (HRMS ESI-TOF), 
m/z: 472.1656 [M + Na]+ (calcd. for C25H27N3NaO3S: 




[1,3,5]thiadiazine-9-carbonitrile (8c). Yield 91%, beige 
crystals. IR spectrum, ν, cm–1: 2201 s (С≡N), 1684 s 
(С=О). 1Н NMR spectrum, δ, ppm: 1.30 t (3Н, OCH2CH3, 
3J = 7.0 Hz), 2.69 d. d (1H, cis-С7H, 2J = 16.1, 3J = 
4.8 Hz), 3.02 d. d (1H, trans-С7H, 2J = 16.1, 3J = 7.1 Hz), 
3.71 s (3H, MeO), 3.74 s (3H, MeO), 3.79 s (3H, MeO), 
3.83–3.85 m (1H, С8H), 3.96 q (2H, OCH2CH3, 3J = 
7.0 Hz), 5.10–5.28 m (4Н, NСН2NCH2S), 6.45–6.48 m 
(2H, H4 N-Ar + H6 C-Ar), 6.60 d (1H, H3N-Ar, 4J = 
2.3 Hz), 6.75 d (1H, H5 C-Ar, 3J = 8.3 Hz), 6.79 d (1H, 
H2 C-Ar, 4J = 1.4 Hz), 7.01 d (1H, H6N-Ar, 3J = 8.7 Hz). 
13С DEPTQ NMR spectrum, δC, ppm: 14.8* (CH3CH2O), 
37.3* (C8H), 38.2 (C7H2), 54.7 (C2H2), 55.3* (CH3O 
C-Ar), 55.4* (4-CH3O N-Ar), 55.7* (2-CH3O N-Ar), 
60.4 (C4H2), 63.6 (CH3CH2O), 88.7 (C9), 100.0* (C3H 
N-Ar), 104.2* (C5HN-Ar), 111.0* (C2H C-Ar), 112.6* 
(C5H C-Ar), 117.9 (C≡N), 118.2* (C6H C-Ar), 121.0* 
(C6H N-Ar), 127.3 (C1 N-Ar), 132.1 (C1 C-Ar), 147.3 
(C4-OEt C-Ar), 149.0 (C3–OMe C-Ar), 149.3 (C9a), 152.8 
(C2–OMe N-Ar), 157.1 (C4–OMe N-Ar), 167.3 (C=O). 
Mass spectrum (HRMS ESI-TOF), m/z: 504.1552 [M + 
Na]+ (calcd. for C25H27N3NaO5S: 504.1564), 572.1417 




N-(4-fluorophenyl)acetamide (9). A mixture of 
cyanothioacetamide 1 (2.0 g, 20 mmol), vanillin (3.04 g, 
20 mmol), 25 mL of ethanol and 3 drops of piperidine 
was stirred until the starting reagents consumed and an 
orange Knoevenagel condensation product formed. To the 
resulting suspension were added 1,3-cyclohexanedione 
(2.24 g, 20 mmol) and piperidine (2.5 mL, 25 mmol). The 
mixture was stirred for 8 h, then acidifi ed with 10% HCl 
in ethanol to pH 5. After 12 h, the precipitate was fi ltered 
off and washed with cooled alcohol. 4-(4-Hydroxy-3-
methoxyphenyl)-2-mercapto-5-oxo-1,4,5,6,7,8-hexa-
hydroquinoline-3-carbonitrile 16 was obtained (yield 
67%), which was used in the next step without additional 
purifi cation.
To a suspension of 2-mercaptoquinoline 16 (660 mg, 
2 mmol) in 15 mL of 85% ethanol were added an 
aqueous 10% KOH solution (1.05 mL, 2 mmol) and 
N-(4-fluorophenyl)-α-chloroacetamide (375 mg, 
2 mmol). The resulting mixture was stirred for 12 h at 
25°С. The precipitated compound 9 was fi ltered off and 
recrystallized from an acetone–ethanol mixture. Yield 
86%, beige powder. IR spectrum, ν, cm–1: 3433 s, 3309 s, 
3282 br, 3221 br, 3095 (O–H, N–H), 2189 s (С≡N), 
1672 s (С=О), 1651 s [С(O)NH]. 1Н NMR spectrum, δ, 
ppm: 1.75–1.93 m (2Н, C7H2), 2.21–2.25 m (2Н, C6H2), 
2.49–2.59 m (2Н, C8H2), 3.70 s (3H, MeO), 3.90 q (2H, 
SCH2, 2J = 14.7 Hz), 4.40 s (1H, H4), 6.53 d. d (1H, 
H6 Ar, 3J = 8.1, 4J = 1.7 Hz), 6.64 d (1H, H5 Ar, 3J = 
8.1 Hz), 6.70 d (1H, H2 Ar, 4J = 1.7 Hz), 7.14–7.18 m (2H, 
H3, H5 4-FC6H4), 7.52–7.56 m (2H, H2, H6 4-FC6H4), 
8.86 s (1H, OH), 9.99 s (1H, N1H), 10.39 s [1H, C(O)
NH]. 13С DEPTQ NMR spectrum, δC, ppm: 20.7 (C7H2), 
26.3 (C8H2), 36.7 (C6H2), 36.8 (SCH2), 38.6* (C4H), 
55.5* (OMe), 92.0 (C3), 109.2 (C4a), 111.5* (C2H Ar), 
115.4* (C5H Ar), 115.5* d (С3H, C5H 4-FC6H4, 2JCF = 
22.4 Hz), 119.1 (C≡N), 119.4* (C6H Ar), 121.4* d (С2H, 
C6H 4-FC6H4, 3JCF = 8.1 Hz), 134.8 d (С1 4-FC6H4, 
4JCF = 2.4 Hz), 136.1 (C1 Ar), 142.1 (C2), 145.5 
(C4–OH Ar), 147.4 (C5–OMe Ar), 151.3 (C8a), 158.3 
d (С4 4-FC6H4, 1JCF = 240.6 Hz), 166.6 [C(O)NH], 
194.9 (C=O). Mass spectrum (HRMS ESI-TOF), m/z: 




tetrahydropyridine-3-carboxylic acid (10). A 
mixture of cyanothioacetamide 1 (2.0 g, 20 mmol), 
2-fluorobenzaldehyde (2.1 mL, 20 mmol), and 
diethylmalonate (3.05 ml, 20 mmol) was stirred in 
25 mL of ethanol in the presence of an excess of 
N-methylmorpholine (25 mmol) for 7 days. The 
precipitate of tetrahydropyridine-2-thiolate 17 was 
fi ltered off, washed with acetone, and dried in air. Yield 
44%, white powder. Thiolate 17 was used without further 
purifi cation.
A mixture of thiolate 17 (2 mmol) and α-chloro-
N-(2-ethylphenyl)acetamide (2 mmol) was heated in 
15 mL of 85% ethanol until the starting reagents were 
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completely dissolved and a clear solution was formed. 
After 24 h, the crystallized product 10 was fi ltered off, 
washed with ethanol and petroleum ether. Yield 83%, 
beige powder. IR spectrum, ν, cm–1: 3325 s (N–H), 2208 s 
(С≡N), 1732 s (С=О), 1693 s [С(O)NH], 1655 s [С(O)
NH]. 1Н NMR spectrum, δ, ppm: 0.97 t (3Н, ArCH2CH3, 
3J = 7.8 Hz), 1.12 t (3Н, OCH2CH3, 3J = 7.1 Hz), 2.59 q 
(2Н, ArCH2CH3, 3J = 7.8 Hz), 3.97–4.04 m (5Н, SCH2, 
H4, OCH2), 4.55 d (1Н, Н3, 3J = 10.8 Hz), 7.18–7.22 m 
(3Н, H-Ar), 7.24–7.27 m (2Н, H-Ar), 7.31–7.42 m (3Н, 
H-Ar), 9.79 s (1H, NHAr), 11.28 s (1H, NH). 13С DEPTQ 
NMR spectrum, δC, ppm: 13.7* (CH3CH2Ar), 14.83* 
(CH3CH2O), 23.6 (CH3CH2Ar), 35.3 (SCH2), 36.8* d 
(С4Н, 3JCF = 1.7 Hz), 52.1* (С3), 61.2 (CH3CH2O), 91.2 
(C5), 115.9* d (С3H 2-FC6H4, 2JCF = 21.5 Hz), 116.7 
(C≡N), 123.7 d (С1 2-FC6H4, 2JCF = 13.4 Hz), 124.9* d 
(С5H 2-FC6H4, 4JCF = 3.1 Hz), 126.01* (СH N-Ar), 
126.04* (СH N-Ar), 126.3* (СH N-Ar), 128.6* (СH 
N-Ar), 129.6* d (С6H 2-FC6H4, 3JCF = 3.3 Hz), 130.5* d 
(С4H 2-FC6H4, 3JCF = 8.4 Hz), 134.8 (C2 N-Ar), 138.2 
(C1 N-Ar), 147.2 (C6), 160.2 d (С2 2-FC6H4, 1JCF = 
246.3 Hz), 165.2 [C(O)NH], 166.8 [C(O)NH], 167.3 
(CO2Et). Mass spectrum (HRMS ESI-TOF), m/z: 




carbonitrile (11). A mixture of cyanothioacetamide 1 
(200 mg, 2 mmol), veratraldehyde (333 mg, 2 mmol), 
and piperidine (1 drop) in 5 mL of ethanol was stirred 
for 5 min until an orange precipitate of the Knoevenagel 
condensation product was formed. To the resulting 
suspension, dimedone (5,5-dimethylcyclohexane-1,3-
dione) (280 mg, 2 mmol) and piperidine (0.25 mL, 
2.5 mmol) were added with vigorous stirring. The 
resulting mixture was stirred until dissolved, fi ltered 
through a paper fi lter and kept for 24 h; in this case, the 
formation of a white fi ne-crystalline precipitate of the 
Michael adduct can be observed. Iodomethane (0.15 mL, 
2.4 mmol) and 4 mL of 70% ethanol were added to 
the reaction mixture. The mixture was slowly heated 
to boiling with stirring, boiled for 10 min, then fi ltered 
through a paper fi lter and allowed to crystallize. The 
precipitate of quinoline 11 was fi ltered off, washed with 
ethanol, petroleum ether, and dried in air. Yield 74%, 
beige powder. IR spectrum, ν, cm–1: 3252, 3173 w (N–H), 
2195 s (С≡N), 1606 br. s (С=О, С=С). 1Н NMR spectrum, 
δ, ppm: 0.91 s (3Н, С7СН3), 1.02 s (3Н, С7СН3), 2.02 
d (1Н, С6Н2, 2J = 16.4 Hz, АВ-system), 2.21 d (1Н, 
С6Н2, 2J = 16.4 Hz, АВ-system), 2.43 q (2Н, С8Н2, 2J = 
17.6 Hz), 2.48 s (3Н, SCH3), 3.67 s (3Н, OCH3), 3.69 s 
(3Н, OCH3), 4.38 s (1Н, H4), 6.63 d. d (1H, H6 Ar, 3J = 
8.3, 4J = 2.0 Hz), 6.69 d (1H, H2 Ar, 4J = 2.0 Hz), 6.86 d 
(1H, H5 Ar, 3J = 8.3 Hz), 9.61 s (1H, NH). 13С DEPTQ 
NMR spectrum, δC, ppm: 15.8* (SCH3), 26.3* (C7CH3), 
29.1* (C7CH3), 32.0 (C7), 38.6* (C4H), 39.3 (C8H2), 50.1 
(C6H2), 55.4* (OMe), 55.5* (OMe), 90.3 (C3), 108.2 
(C4a), 110.8* (C2H C-Ar), 111.8* (C5H C-Ar), 118.95* 
(C6H C-Ar), 118.99 (C≡N), 137.7 (C1 C-Ar), 144.5 (C8a), 
147.7 (COMe), 148.6 (COMe), 149.6 (C2), 194.6 (C=O). 
Mass spectrum (HRMS ESI-TOF), m/z: 407.1393 [M + 
Na]+ (calcd. for C21H24N2NaO3S: 407.1400).
The study of analgesic activity was carried out on 56 
white outbred sexually mature rats of both sexes weighing 
160–200 g in the autumn-winter period. Throughout the 
experiment, the animals were kept in a vivarium, the 
diet was standard, there were no more than 6 individuals 
in the cage, which corresponds to the guidelines for 
ethical review of biomedical research [68, 69]. In the 
pre-experimental period, a thorough examination of the 
animals was carried out, special attention was paid to 
their weight, age, physical activity and the animal coat. 
Based on these data, laboratory rats were evenly divided 
into groups: intact, control (with simulated orofacial 
trigeminal pain and heat tail immersion), reference 
(ketorolac), and 6 experimental groups according to the 
number of α-cyanothioacetamide derivatives studied.
Proceeding from the principles of humanity, the 
experiment was carried out with the minimum number 
of animals (6 per group) permissible for statistical 
processing and obtaining reliable results, as well as the 
minimum number of experimental groups to achieve the 
set goals and objectives. The assessment of analgesic 
activity was carried out in the test of orofacial trigeminal 
pain, which was simulated by the subcutaneous injection 
of 0.1 mL of a 5% formalin solution into the vibrissa area 
in laboratory rats [69]. Within 20 min (for 10, 15 and 
20 min) after the introduction of algogen, the number of 
scratching movements with the front paws of the orofacial 
area was counted. Ketorolac at a dose of 0.1 mg/kg was 
used as a reference drug for the reference group of rats; 
6 samples of the tested pyridine derivatives were injected 
intragastrically at a dose of 5 mg/kg 1.5 hours before the 
administration of the algogen (formalin) used.
To evaluate thermal pain, we chose the method of 
thermal tail immersion, based on the spinal fl exor refl ex 
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in response to immersion of the tail in hot water. Painful 
irritation was simulated by immersing the tail in a vessel 
with water heated to 50–54°C, while measuring the value 
of the latent period of the reaction. Analgesic activity 
was assessed by lengthening the tail fl ick reaction time.
The results were statistically processed using the 
Statistica 10.0 software package. Since the study was 
carried out on the smallest possible number of laboratory 
animals, nonparametric methods were used in the analysis 
of the numerical results of the experimental part of the 
work. In order to determine the reliability of differences 
in statistical data processing, a nonparametric Wilcoxon 
matched-pairs signed ranks test was used with preliminary 
determination of valid intervals of values for each of the 
studied indicators. In this case, the samples were assessed 
as continuous, suffi cient in terms of the variability of the 
feature [70]. The signifi cance of differences between 
the values of the control and experimental groups was 
calculated on the basis of the data obtained (median, 
quartile, mean values, standard deviation).
This work was performed in compliance with all 
applicable international, national and institutional 
guidelines for the care and use of animals.
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